Scarica l'app Stockscreener
9.32
13.38%
1.10
Dopo l'orario di chiusura:
9.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAMP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.22
Aprire:
$8.3
Volume 24 ore:
113.27K
Relative Volume:
0.57
Capitalizzazione di mercato:
$181.79M
Reddito:
$264.74M
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-16.35
EPS:
-0.57
Flusso di cassa netto:
$-3.08M
1 W Prestazione:
-18.03%
1M Prestazione:
+2,230%
6M Prestazione:
+153.26%
1 anno Prestazione:
+59.53%
Intervallo 1D:
$8.26
$9.8099
Intervallo di 1 settimana:
$7.80
$11.29
Portata 52W:
$0.3901
$87.50
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Nome
Camp 4 Therapeutics Corp
Settore
Industria
Telefono
-
Indirizzo
-
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-08-16 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2021-12-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2021-09-24 | Reiterato | Craig Hallum | Buy |
| 2021-06-25 | Reiterato | Craig Hallum | Buy |
| 2020-12-18 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-04-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-05 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Downgrade | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-01 | Reiterato | Craig Hallum | Buy |
| 2019-03-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-01-25 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-12-21 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2018-12-14 | Reiterato | B. Riley FBR | Buy |
| 2018-12-11 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | Iniziato | Goldman | Neutral |
| 2018-10-15 | Iniziato | Jefferies | Hold |
| 2018-09-28 | Reiterato | Craig Hallum | Hold |
| 2018-04-27 | Reiterato | Craig Hallum | Hold |
| 2018-03-08 | Downgrade | Craig Hallum | Buy → Hold |
| 2018-02-16 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
Mostra tutto
Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
Camp4 gains after earning bullish views on Street - MSN
Camp4 stock gains after earning bullish views (CAMP:NASDAQ) - Seeking Alpha
William Blair upbeat on CAMP4 shares with Outperform rating - Investing.com
Leerink sets stock target for CAMP4, cites broad UCD treatment potential - Investing.com India
JPMorgan sees "breakthrough potential" in CAMP4 stock, bets big on RNA tech - Investing.com India
Piper Sandler optimistic on CAMP4 stock, cites potential in pioneering RNA technology - Investing.com
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
Warren Buffett and Biotech IPOs Highlight Recent Insider Buying - 24/7 Wall St.
Camp4 Therapeutics sees $8.4 million stock purchase by Northpond Ventures - Investing.com India
Camp4 Therapeutics sees $7.99m stock purchase by investors By Investing.com - Investing.com India
Insider Trading Recap: Thursday's Top Buys and Sells in US Stocks - Investing.com India
CAMP4 Rings the Opening Bell - Nasdaq
Insider Trading Activity Tuesday: Top Buys and Sells in US Stocks Revealed - Investing.com
Camp4 Therapeutics sees $9.99 million stock purchase by Polaris - Investing.com
Camp4 Therapeutics sees $9.99 million stock purchase by 5AM Ventures - Investing.com Australia
Camp4 Therapeutics director Nashat Amir buys $9.99m in stock - Investing.com India
Camp4 Therapeutics director Nashat Amir buys $9.99m in stock By Investing.com - Investing.com Australia
Camp4 Therapeutics director Andrew Schwab buys $9.99m in stock - Investing.com
Camp4 Therapeutics director Andrew Schwab buys $9.99m in stock By Investing.com - Investing.com South Africa
Upstream Bio and Camp4 and Ceribell Transactions - William Blair
CAMP4 Therapeutics’ $75 Million IPO - Global Legal Chronicle
Opening Day: Another trio of biotech IPOs make Friday debut - Yahoo Finance
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
CAMP4 stock edges up 2% following $75M IPO - MSN
Upstream catches aftermarket updraft, as Camp4 IPO gets muted reception - BioCentury
Finance Watch: 2024 Has Now Beaten 2023’s Total Of 21 IPOs - Scrip
Upstream Bio Shares Rise 26% to Lead Burst of Life Sciences IPOs - MSN
6 Firms Guide IPO Trio From Biotech, Medical Device Cos. - Law360
Form 424B4 Camp4 Therapeutics Corp - StreetInsider.com
CAMP4 stock edges up 2% following $75M IPO (NASDAQ:CAMP) - Seeking Alpha
Camp4 Therapeutics Opens At $11.16, IPO Priced At $11 - Investing.com
CAMP4's turn to "dark side" shows promise, with $75 million IPO - The Pharma Letter
CAMP4 Therapeutics prices $75MIPO at $11 per share - MSN
RNA biotech CAMP4 Therapeutics prices IPO below the range at $11; adds shares to keep deal size at $75 million - Renaissance Capital
CAMP4 Therapeutics Prices 6.82M Share IPO at $11/sh By Investing.com - Investing.com South Africa
CAMP4 Therapeutics Prices 6.82M Share IPO at $11/sh - Investing.com
CAMP4 Therapeutics To Debut On Nasdaq Today - RTTNews
CAMP4 Announces Pricing of Initial Public Offering - ForexTV.com
Camp 4 Therapeutics Corp Azioni (CAMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):